Medtronic (MDT) Posted Positive Real World Ablation Data

• Medtronic (NYSE:MDT) reported positive real-world outcomes for its Affera Mapping and Ablation System in atrial fibrillation and ventricular tachycardia patients.

• The business also highlighted favorable real-world data for its PulseSelect Pulsed Field Ablation System across a broad cardiac ablation patient group.

• Medtronic appointed Michael Marinaro as President, adding responsibility for the group's operations in Greater China.

• The fresh Affera and PulseSelect clinical results, together with Marinaro's expanded role, only capture part of today's Medtronic story. Take a look at 5 other big wins we have identified for Medtronic.

This focus on Medtronic's ablation push is only one angle. Several other companies also tie into this broader medical technology trend 41 profitable AI stocks that aren't just burning cash .

Medtronic, a US medical equipment group with a market value of about $118.2b, sells device-based therapies to hospitals and clinicians worldwide. Progress in cardiac ablation tools and leadership coverage in Greater China directly touches two large commercial and clinical arenas for the business.

Does the team leading Medtronic have what it takes? See our full breakdown of the management team's track record and compensation.

Medtronic's ablation data backs the higher growth cardiovascular catalyst, but keeps mix risk in play

This real world ablation readout lines up neatly with the Medtronic Narrative catalyst that leans on Cardiac Ablation Solutions and broader cardiovascular strength to support revenue and earnings over time. Strong registry outcomes in AFib and VT help reinforce the idea that higher vitality electrophysiology platforms can carry more of the growth load as the MiniMed diabetes separation and cost programs reshape the portfolio. At the same time, the focus on ablation adds to the live risk flagged in the Narrative that faster growing but lower margin businesses, including Cardiac Ablation Solutions, can dilute the margin uplift Medtronic is targeting.

See how these catalysts shape Medtronic's path to a $105 fair value .

For investors watching execution, a practical checkpoint is the next detailed update on Cardiac Ablation Solutions and PulseSelect adoption in Medtronic's quarterly results, including how this mix shows up in segment level margins and whether management ties the new data to any change in R&D or capital allocation priorities.

One more Medtronic question that matters for investors

All of this still leaves one big piece missing for Medtronic watchers. There is an estimate of what the business could be worth based purely on its cash generation versus today's share price. Find out exactly what Medtronic is worth today based on its cash flows .